+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06578104

Observational Study of PulseSelect PFA System for Atrial Fibrillation Treatment and Follow-up

Led by Medtronic Cardiac Ablation Solutions · Updated on 2026-10-28

580

Participants Needed

23

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a global, multi-center observational trial to study patients with recurrent symptomatic paroxysmal or persistent atrial fibrillation AF. The trial evaluates the PulseSelect PFA System, a market-approved device used for pulmonary vein isolation, to better understand its safety and effectiveness over a 36-month period. This study follows patients who have not responded well to at least one Class I or III antiarrhythmic drug. Participants will undergo an ablation procedure using the PulseSelect PFA System according to standard hospital care. The study observes two groups based on AF type paroxysmal and persistent. After treatment, patients will be followed with scheduled visits at 3, 6, 12, 24, and 36 months, including 24-hour Holter heart monitoring at the 6, 12, 24, and 36 month visits. During the study, participants will have regular assessments to track heart rhythm and safety outcomes. Researchers will measure freedom from atrial fibrillation at 36 months after ablation and monitor for device- or procedure-related adverse events up to 6 months. The total participant involvement spans three years, providing long-term data on treatment outcomes and safety.

CONDITIONS

Brief Title

PULSED AF Post-Approval Study

Research Team

J

Josman Suri

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here